Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency

Barcelona (Spain), May 23, 2018.- Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), a global company that enhances the health and well-being of patients through the development of life-saving plasma-derived medicines, clinical diagnostics and pharmaceutical specialities for hospital use, today announced the publication of its 2017 Corporate Responsibility Report. The report highlights Grifols' firm commitment and pledge of transparency to its stakeholders, which include, among others, donors, patients, medical professionals, employees and society as a whole.

The information contained therein offers an in-depth view of Grifols' social engagement initiatives, ongoing training, commitment to inclusion and diversity, environmental actions, and respect for human rights and business ethics in compliance with Sustainability Reporting Standards of Global Reporting Initiative (GRI Standards).

Grifols' Corporate Responsibility Report covers the 2017 fiscal year, using a materiality analysis as its basis. The report was verified by an external independent company and approved by Grifols' Board of Directors on April 27, 2018.

Grifols aspires to continue to contribute toward economic, environmental and social progress on local, regional and global levels. The information relating to its 2017 performance is contextualized within the framework of the regions where it operates.

The report is available for download on Grifols' website: www.grifols.com